KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Net Margin (2019 - 2025)

Aurinia Pharmaceuticals' Net Margin history spans 7 years, with the latest figure at 273.35% for Q4 2025.

  • For Q4 2025, Net Margin rose 27096.0% year-over-year to 273.35%; the TTM value through Dec 2025 reached 101.46%, up 9902.0%, while the annual FY2025 figure was 101.45%, 9900.0% up from the prior year.
  • Net Margin reached 273.35% in Q4 2025 per AUPH's latest filing, up from 42.95% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 273.35% in Q4 2025 to a low of 5511.93% in Q1 2021.
  • Average Net Margin over 5 years is 345.75%, with a median of 26.18% recorded in 2023.
  • Peak YoY movement for Net Margin: surged 14493322bps in 2021, then crashed -855bps in 2023.
  • A 5-year view of Net Margin shows it stood at 142.38% in 2021, then surged by 36bps to 91.6% in 2022, then skyrocketed by 35bps to 59.58% in 2023, then soared by 104bps to 2.39% in 2024, then surged by 11352bps to 273.35% in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Net Margin are 273.35% (Q4 2025), 42.95% (Q3 2025), and 30.73% (Q2 2025).